sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
emerg
causal
agent
endem
atyp
pneumonia
infect
thousand
peopl
worldwid
although
number
promis
potenti
vaccin
therapeut
agent
sarscov
describ
effect
antivir
drug
sarscov
current
avail
intric
sequenti
natur
viral
entri
process
provid
multipl
valid
target
drug
develop
describ
rapid
safe
cellbas
highthroughput
screen
system
dual
envelop
pseudovirion
dep
assay
specif
screen
inhibitor
viral
entri
assay
system
employ
novel
dual
envelop
strategi
use
lentivir
pseudovirion
target
whose
entri
driven
sarscov
spike
glycoprotein
second
unrel
viral
envelop
use
intern
control
reduc
number
fals
posit
exampl
power
assay
class
inhibitor
report
potenti
inhibit
sarscov
two
step
replic
cycl
viral
entri
particl
assembl
assay
system
easili
adapt
screen
entri
inhibitor
virus
care
select
match
partner
viru
envelop
sarscov
emerg
pathogen
respons
global
outbreak
atyp
pneumonia
although
number
promis
potenti
vaccin
therapeut
agent
sarscov
describ
review
golda
pyrc
unclear
like
becom
therapeut
use
particular
although
neutral
monoclon
antibodi
identifi
rockx
et
al
divers
sarscovlik
sequenc
found
anim
reservoir
make
antigen
select
vaccin
develop
difficult
prior
new
zoonot
transmiss
deme
et
al
liu
et
al
number
stage
sarscov
life
cycl
repres
attract
target
potenti
antisarscov
therapeut
enzymat
process
polymeras
proteas
activ
often
good
target
antivir
due
special
mode
action
trial
use
small
anim
model
howev
less
promis
mani
candid
fail
inhibit
viral
replic
vivo
barnard
et
al
inhibit
viral
entri
appeal
drug
target
mani
virus
includ
sarscov
prevent
initi
step
toward
viral
replic
inde
viru
entri
major
focu
drug
develop
sever
inhibitor
either
market
clinic
trial
multipl
step
entri
process
valid
target
inhibit
includ
attach
receptor
engag
viral
intern
envelop
conform
rearrang
membran
fusion
use
pseudovirion
identifi
small
molecul
entri
inhibitor
difficult
handl
andor
highli
pathogen
bsl
virus
lassa
viru
recent
describ
garcia
et
al
larson
et
al
york
et
al
inde
use
pseudovirion
complement
live
viru
previous
demonstr
inhibitor
cystein
proteas
leupeptin
act
potent
inhibitor
sarscov
entri
simmon
et
al
inhibit
result
absolut
requir
cell
line
endosom
process
spike
glycoprotein
cathepsin
l
ctsl
entri
target
cell
simmon
et
al
simmon
et
al
vivo
situat
complic
number
secret
surfac
proteas
presenc
respiratori
tract
cellular
type
ii
transmembran
serin
proteas
ttsp
abl
mediat
sarscov
entri
via
nonendosom
rout
kam
et
al
describ
rapid
safe
cellbas
highthroughput
screen
ht
assay
system
specif
screen
inhibitor
viral
entri
use
lentivir
pseudovirion
whose
entri
driven
sarscov
spike
glycoprotein
preliminari
studi
found
mani
initi
hit
identifi
potenti
inhibitor
entri
mediat
envelop
phdepend
virus
sarscov
mildli
toxic
least
cell
line
candid
inhibitor
also
often
abl
inhibit
mani
envelop
virus
like
due
subtl
effect
cellular
function
endocytosi
data
shown
order
overcom
obstacl
earli
stage
second
unrel
viral
envelop
util
order
reduc
number
fals
posit
hit
obtain
primari
screen
target
gener
small
molecul
librari
screen
inhibitor
sarscov
entri
number
compound
identifi
inhibit
sarscov
entri
replic
human
embryon
kidney
cell
clone
obtain
atcc
grown
dulbecco
modifi
eagl
medium
dmem
invitrogen
supplement
fb
penicillin
streptomycin
uml
stabli
express
human
angiotensin
convert
enzym
establish
transfect
cell
invitrogen
encod
gene
select
stabl
transform
use
blasticidin
lgml
control
inhibitor
includ
dideoxythymidin
azt
sigmaaldrich
inhibitor
pseudovirion
leupeptin
zphephefmk
emd
bioscienc
inhibitor
sarscov
entri
larson
et
al
lassa
antimurin
leukemia
viru
mlv
antibodi
inhibit
mlv
gift
dr
leonard
evan
rocki
mountain
laboratori
pseudotyp
virus
gener
two
plasmid
one
encod
envelop
encod
viral
backbon
report
gene
plasmid
encod
sarscov
spike
glycoprotein
ebola
gp
vesicular
stomat
viru
vsv
g
chikungunya
viru
chikv
well
mlv
envelop
describ
gilbert
et
al
salvador
et
al
simmon
et
al
simmon
et
al
simmon
et
al
lassa
gp
gene
synthes
base
sequenc
strain
subclon
envelopedefici
hiv
report
construct
lucr
e
pnlluc
encod
replicationincompet
variant
molecular
clone
nef
gene
replac
firefli
luciferas
luc
report
env
vpr
gene
inactiv
previous
describ
connor
et
al
similarli
e
construct
swap
firefli
luciferas
gene
renilla
luciferas
use
noti
xhoi
pseudovirion
produc
essenti
previous
describ
simmon
et
al
briefli
cell
transfect
lg
viral
envelop
encod
plasmid
lg
report
backbon
per
dish
use
calcium
phosphat
next
day
express
induc
sodium
butyr
mm
h
wash
forti
hour
transfect
supernat
filter
lmpores
filter
frozen
result
report
virus
classifi
accord
report
system
viral
envelop
exampl
hivluc
sarscov
hivren
lassa
gp
viru
titrat
use
condit
describ
screen
assay
compound
librari
divers
candid
cystein
proteas
inhibitor
collect
rang
academ
industri
sourc
curat
ucsf
sandler
center
drug
discoveri
previous
describ
goetz
et
al
screen
gener
small
molecul
compound
librari
purchas
chemdiv
curat
ucsf
small
molecul
discoveri
core
also
screen
synthes
previous
describ
goetz
et
al
roush
et
al
synthet
inhibitor
puriti
determin
nmr
analysi
except
isol
test
insepar
mixtur
epoxid
diastereom
highthroughput
screen
inhibitor
sarscovmedi
entri
perform
either
format
use
white
tissu
cultur
plate
nunc
initi
dimethyl
sulfoxid
dmso
stock
compound
mm
use
prepar
dilut
plate
mm
use
dmso
assay
format
compound
dilut
dmem
fb
give
concentr
lm
dmso
posit
inhibit
control
lm
azt
neg
control
medium
alon
also
adjust
contain
dmso
ten
test
compound
azt
medium
alon
transfer
blank
assay
well
use
biomek
fxp
beckmancoult
mixtur
target
viru
hivluc
sarscov
control
viru
ie
hivren
lassa
gp
hivren
mlv
env
made
rel
deriv
empir
give
similar
robust
level
report
express
thirti
report
viru
mix
ad
well
use
matrix
wellmat
thermo
scientif
fast
set
smallbor
tube
cell
remov
tissu
cultur
dish
use
versin
wash
resuspend
cell
per
millilit
steril
bottl
gentl
agit
use
magnet
stirrer
use
wellmat
cell
ad
well
medium
set
standardbor
tube
thu
compound
use
final
concentr
lm
dmso
cell
per
well
plate
incub
two
day
co
firefli
renilla
luciferas
report
express
determin
use
dualglo
luciferas
assay
system
promega
sequenti
addit
wellmat
luminesc
determin
polarstar
bmg
labtech
first
luciferas
reagent
stopandglo
assay
perform
similarli
assay
format
except
compound
control
deliv
lm
dmso
togeth
report
viru
mix
cell
cell
per
millilit
level
viral
infect
determin
compon
dualglo
system
test
run
determin
assay
robust
perform
medium
contain
dmso
give
final
assay
concentr
assay
dose
respons
curv
perform
white
tissu
cultur
plate
nunc
compound
serial
dilut
medium
maintain
concentr
dmso
ten
test
compound
medium
alon
transfer
assay
well
follow
either
singl
viru
two
report
viru
mixtur
depend
purpos
assay
cell
cell
per
millilit
well
plate
incub
two
day
co
firefli
renilla
luciferas
report
express
determin
use
dualglo
luciferas
assay
system
promega
detect
firefli
luciferas
report
express
use
luciferas
assay
system
promega
cell
viabil
assay
cell
seed
black
tissu
cultur
plate
costar
coat
compound
final
concentr
dmso
quantiti
atp
present
metabol
activ
cell
determin
celltiterglo
luminesc
cell
viabil
assay
system
promega
madison
wi
standard
method
assess
qualiti
ht
assay
dimensionless
calcul
z
prime
z
statist
calcul
perform
excel
made
follow
z
standard
deviat
sd
maximum
signal
control
sd
minimum
signal
control
mean
maximum
signal
control
mean
minimum
signal
control
cv
sd
mean
zhang
et
al
z
valu
plate
greater
gener
good
indic
adequ
assay
zhang
et
al
compound
primari
screen
consid
inhibitori
luciferas
read
sarscov
intern
control
pseudotyp
virus
fell
predefin
cutoff
assay
use
simultan
infect
includ
control
pseudovirion
encod
renilla
luciferas
incorpor
irrelev
envelop
mlv
envelop
thu
toxic
nonspecif
inhibit
control
cell
pretreat
inhibitor
follow
equal
volum
hivluc
sarscov
hivren
mlva
env
cell
h
firefli
luciferas
renilla
analyz
sequenti
use
twostep
detect
system
promega
medison
wi
ic
inhibitori
concentr
ic
valu
calcul
use
nonlinear
regress
analysi
base
sigmoid
dose
respons
equat
use
prism
softwar
appli
percent
inhibit
concentr
data
develop
novel
dual
envelop
pseudovirion
dep
assay
screen
inhibitor
viral
entri
dual
envelop
strategi
allow
effici
screen
librari
introduc
intern
control
primari
screen
fig
widerang
paramet
examin
optim
includ
plate
type
dispens
method
time
cell
addit
cell
number
pseudovirion
dmso
concentr
data
shown
possibl
interfer
two
envelop
could
occur
either
inhibit
entri
overcom
inhibit
order
verifi
case
entri
inhibit
pseudoparticl
variant
test
separ
combin
tabl
assay
carri
differ
dual
pseudoviru
combin
one
encod
test
viral
envelop
firefli
luciferas
report
hivluc
viral
env
encod
control
viral
envelop
renilla
luciferas
hivren
viral
env
compar
individu
viru
alon
h
infect
pseudovirion
particl
term
rel
light
unit
firefli
renilla
luciferas
analyz
sequenti
studi
determin
envelop
vsvg
unsuit
use
dual
envelop
assay
use
hivluc
vsvg
led
almost
univers
increas
infect
hivren
virus
tabl
similarli
hivluc
virus
enhanc
hivren
vsvg
possibl
due
highli
fusogen
natur
vsvg
notabl
number
specif
combin
pseudotyp
virus
also
appear
incompat
tabl
exampl
combin
hivluc
mlv
env
hivren
sarscov
yield
infect
compar
singl
viru
control
respect
although
invers
respect
moreov
mix
viru
firefli
renilla
luciferas
report
also
show
decreas
infect
compar
singl
viru
alon
especi
pseudovirus
sarscov
mlv
env
ebola
gp
like
due
competit
low
level
receptor
virus
two
differ
report
util
known
inhibitor
determin
whether
inclus
second
viru
would
advers
affect
abil
inhibitor
specif
block
infect
cystein
proteas
inhibitor
leupeptin
highli
effect
sarscov
entri
cell
line
simmon
et
al
recent
identifi
inhibitor
arenaviru
entri
larson
et
al
dose
respons
curv
two
inhibitor
class
superimpos
mix
individu
pseudovirion
infect
fig
b
leupeptin
exhibit
dosedepend
inhibit
sarscov
infect
hivluc
sarscov
hivren
sarscov
regardless
whether
partner
lassa
gp
pseudovirion
present
thu
presenc
irrelev
envelop
interfer
inhibit
specif
inhibitor
dose
respons
curv
sarscov
spike
envelop
combin
also
assess
found
give
similar
result
sarscov
spike
lassa
gp
includ
envelop
mlv
fig
chikv
data
shown
result
indic
dual
pseudovirion
system
sarscov
lassa
gp
mlv
chikv
suitabl
use
ht
inhibitor
sarscovmedi
entri
studi
also
demonstr
issu
signal
quench
dual
assay
carryov
fals
signal
loss
true
signal
proceed
ht
analyz
perform
assay
system
without
ad
compound
exampl
assay
evalu
combin
hivluc
sarscov
hivren
lassa
gp
five
plate
indic
hivren
lassa
gp
interpl
coeffici
variat
cv
z
similarli
hivluc
sarscov
cv
equal
z
similar
result
observ
format
cv
hivren
lassa
gp
z
cv
hivluc
sarscov
z
ht
inhibitor
sarscovmedi
entri
perform
nunc
plate
assay
optim
final
concentr
compound
lm
dmso
report
viru
mix
hivluc
sarscov
hivren
lassa
gp
hivluc
sarscov
hivren
mlv
env
cell
cell
well
cell
per
well
plate
demonstr
util
dual
envelop
strategi
initi
screen
divers
small
molecul
librari
chemdiv
san
diego
ca
conduct
inhibitor
concentr
lm
fig
exampl
candid
total
compound
identifi
inhibitor
sarscov
mediat
entri
use
cutoff
mean
minu
three
standard
deviat
approxim
equival
reduct
infect
high
hit
rate
like
repres
fact
relat
compound
cluster
librari
inde
number
relat
hit
identifi
nine
candid
correspond
reduct
lassa
gp
pseudovirion
greater
addit
two
candid
reduct
lassa
gp
control
greater
observ
less
variat
lassa
gpbase
pseudovirion
gener
base
past
experi
toxic
util
stricter
criterion
decid
whether
compound
pursu
evalu
thu
inclus
control
pseudoviru
hivren
lassa
gp
found
use
avoid
like
nonspecif
inhibit
promiscu
inhibitor
reduc
hit
rate
third
call
fals
posit
fig
addit
perform
random
screen
small
molecul
inhibitor
sarscov
entri
also
exploit
fact
previous
identifi
specif
aspect
coronaviru
entri
amen
inhibit
simmon
et
al
simmon
et
al
inhibitor
mlv
antibodi
panel
c
sarscov
spike
pseudoviru
without
combin
lassa
gpmlv
env
pseudoviru
result
present
percentag
luciferas
read
drug
control
shown
mean
sd
triplic
measur
repres
experi
least
three
experi
shown
cystein
proteas
ctsl
particular
highli
effect
prevent
sarscov
infect
rel
nontox
vitro
thu
screen
uniqu
collect
cystein
proteas
inhibitor
use
plate
format
expect
inhibitor
profil
larg
number
librari
member
abl
inhibit
entrymedi
sarscov
spike
specif
manner
candid
inhibitor
exhibit
greater
inhibit
sarscov
mediat
entri
inhibit
control
envelop
initi
screen
studi
dose
respons
curv
gener
exampl
dose
respons
curv
proteas
inhibitor
librari
see
fig
group
dipeptidyl
epoxyketon
molecul
identifi
proteas
inhibitor
librari
screen
demonstr
signific
inhibit
sarscov
smediat
infect
fig
interestingli
famili
compound
alreadi
select
previou
screen
librari
potenti
inhibitor
one
sarscov
proteas
goetz
et
al
particular
wrr
wrr
specif
inhibit
live
sarscov
viral
replic
greater
lm
goetz
et
al
even
though
wrr
highli
activ
viral
proteas
studi
compound
wrr
specif
inhibit
sarscov
entri
ic
less
nm
fig
tabl
potent
inhibitor
zphephefmk
market
ctslspecif
wrr
epoxidebas
inhibitor
lphenylalanin
residu
r
configur
epoxid
group
tabl
wrr
epoxid
isom
wrr
less
potent
inhibitor
sarscov
smediat
entri
compar
wrr
fig
tabl
neither
compound
demonstr
detect
cytotox
even
lm
data
shown
goetz
et
al
second
gener
dipeptidylderiv
inhibitor
base
scaffold
epoxyketon
alreadi
synthes
previous
describ
goetz
et
al
viral
inhibit
assay
perform
tabl
hope
compound
capabl
effici
inhibit
viral
proteas
ctsl
could
identifi
number
compound
retain
abil
eight
compound
reduc
sarscov
green
symbol
lassa
gp
brown
symbol
mediat
entri
box
togeth
compound
demonstr
reduct
sarscov
alon
highlight
orang
circl
one
compound
reduc
lassa
gp
highlight
blue
circl
inhibit
viral
proteas
includ
wrr
highli
potent
goetz
et
al
wrr
found
inhibit
sarscov
entri
respect
ic
approxim
nm
somewhat
better
ctslspecif
inhibitor
zphephefmk
fig
howev
compound
found
greatli
increas
toxic
littl
ad
antivir
benefit
goetz
et
al
even
though
ideal
lead
candid
dual
activ
yet
identifi
hope
investig
may
yield
compound
studi
develop
novel
dual
pseudovirionbas
ht
assay
system
lentivir
pseudotyp
particl
system
focus
find
inhibitor
step
viral
entri
minim
risk
associ
hazard
virus
allow
handl
special
facil
would
otherwis
necessari
dep
assay
also
identifi
grossli
toxic
compound
reduc
number
fals
posit
hit
introduc
compound
abl
nonspecif
inhibit
share
cellular
function
mani
virus
exampl
endocytosi
demonstr
system
reduc
number
fals
posit
hit
significantli
allow
earlier
identif
promis
inhibitor
inde
envelop
chosen
care
assay
allow
simultan
screen
two
unrel
envelop
interest
also
act
intern
control
earlier
screen
found
mani
promis
inhibitor
entri
mediat
phdepend
virus
sarscov
abl
inhibit
virus
like
due
toxic
subtl
effect
cellular
function
hit
often
cytotox
common
laboratori
cell
line
show
suffici
sign
toxic
primari
cell
type
hepatocyt
consid
like
drug
candid
data
shown
thu
although
panvir
famili
antivir
attract
goal
gener
avoid
lead
somewhat
unrealist
object
dual
envelop
assay
allow
rapid
earli
identif
elimin
compound
iron
notabl
except
rule
proteas
inhibitor
describ
studi
compound
act
defin
mechan
block
envelop
process
andor
viral
capsid
uncoat
clearli
demonstr
inhibit
filovirus
coronavirus
henipavirus
reovirus
chandran
et
al
ebert
et
al
pager
et
al
pager
dutch
schornberg
et
al
simmon
et
al
thu
care
must
taken
choos
partner
viru
envelop
use
envelop
overlap
function
receptor
specif
target
exampl
use
ebola
gp
sarscov
would
elimin
detect
wrr
seri
compound
entri
mediat
viral
envelop
block
ctsl
inhibitor
inde
assay
could
revers
common
entri
mechan
suspect
order
deliber
search
specif
inhibitor
mechan
select
hit
reduc
virus
base
assay
system
success
initi
screen
two
librari
compound
would
target
viral
entri
process
sarscov
particular
inhibitor
essenti
step
sarscov
spike
proteolysi
cell
line
least
occur
endosom
target
cell
huang
et
al
simmon
et
al
identifi
hope
compound
identifi
assay
specif
abl
inhibit
endsom
proteolyt
process
sarscov
spike
use
anim
studi
determin
whether
ctslendosom
rout
entri
surfac
proteasemedi
fusion
rout
import
vivo
mani
hit
dipeptid
epoxyketon
previous
report
inhibit
one
coronaviru
proteas
goetz
et
al
two
epoxyketon
wrr
wrr
isom
affect
biolog
properti
wrr
potent
fig
epoxyketon
inhibit
sarscov
panel
c
control
envelop
entri
panel
b
result
present
percentag
luciferas
read
drug
control
shown
mean
sd
triplic
measur
repres
experi
least
three
experi
shown
sarscov
chymotrypsinlik
proteas
nevertheless
compound
appear
inhibit
sarscov
replic
vitro
appar
similar
abil
goetz
et
al
demonstr
wrr
highli
activ
sarscov
spikemedi
entri
thu
antivir
properti
two
isom
explain
r
isom
like
act
inhibit
ctsl
activ
contrast
isom
inhibit
replic
due
fact
bind
irrevers
proteas
compound
capabl
inhibit
ctsl
would
target
viru
multipl
step
life
cycl
thu
increas
effici
would
also
like
lessen
chanc
drug
resist
establish
wrr
compound
demonstr
inde
possibl
unfortun
compound
unlik
parent
compound
highli
toxic
possibl
due
wrr
becom
broadli
activ
mani
cellular
proteas
although
demonstr
nevertheless
wrr
repres
potenti
less
toxic
dualli
activ
third
gener
compound
develop
conclus
highli
sensit
rapid
reproduc
assay
system
success
appli
screen
entri
inhibitor
sarscov
moreov
easili
adapt
screen
entri
inhibitor
virus
care
select
match
partner
viru
envelop
interfer
particular
human
coronavirus
togeth
respiratori
virus
metapneumoviru
parainfluenzaviru
caus
signific
morbid
mortal
particularli
among
immunocompromis
patient
ht
assay
entri
inhibitor
dep
assay
describ
provid
good
lead
candid
antivir
drug
develop
sarscov
virus
